Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC:BAYRY) announced that the U.S. FDA has granted Priority Review to a supplemental new drug application for HYRNUO (sevabertinib) as first-line treatment for adults with locally advanced or metastatic HER2-mutated NSCLC who have not received prior therapy, based on preliminary Phase I/II SOHO-01 data.
Bayer (OTC:BAYRY) reported Phase II ARASEC data showing NUBEQA (darolutamide) plus ADT improved outcomes in U.S. patients with metastatic castration-sensitive prostate cancer (mCSPC) versus a matched ADT-alone historical control from CHAARTED.
The regimen reduced risk of progression or death by 71% and showed significant overall survival and rPFS benefits, with no new safety signals but notable design limitations.
Bayer (OTC:BAYRY) launched the Midol in Motion campaign to help menstruators manage 7 common PMS symptoms through symptom relief and supportive movement. The program combines Midol Complete’s multi-symptom relief with guided exercise routines.
The campaign features live workout events, fitness influencer partnerships, and ongoing digital content across Midol’s social channels.
Bayer (OTC:BAYRY) and country artist Luke Bryan launched a 2026 campaign to expand access to food and nutrition in rural America. Bayer will donate 1 million meals through Feeding America, with food drives and Farm Tour events in Clovis and Elk Grove, California, from May 14–16, 2026.
The partnership, active since 2015, has supported more than 11 million meals for Feeding America member food banks and includes community events, canned food collections, and a limited One A Day x Luke Bryan multivitamin available exclusively at Walmart.
Bayer (OTC: BAYRY) reported that the Phase III REVEAL study met its primary endpoints for iodine 124 evuzamitide PET/CT, demonstrating sensitivity and specificity for diagnosing cardiac amyloidosis by visual scan interpretation.
The tracer retains Breakthrough Therapy and Orphan Drug designations; Bayer plans regulatory discussions with the FDA and other authorities and will present full data at a scientific congress.
Bayer (OTC:BAYRY) will acquire Perfuse Therapeutics, gaining full rights to PER-001, a Phase II endothelin receptor antagonist for Glaucoma and Diabetic Retinopathy.
The deal carries up to USD 2.45 billion in total value, including a USD 300 million upfront payment; closing requires antitrust clearances and Perfuse stockholder approval.
Bayer (OTC: BAYRY) will present 13 abstracts at ESOC 2026 (May 6–8, Maastricht), including two late-breaking analyses from the Phase III OCEANIC-STROKE trial of asundexian.
Late breakers cover incident ischemic stroke characteristics and a net clinical benefit/time-course analysis; four OCEANIC-STROKE sub-analyses and nine real-world stroke outcomes studies will also be presented.
Leaps by Bayer (BAYRY), with BCG and Ipsos UK, published a qualitative April 29, 2026 report decoding public attitudes toward breakthrough science across China, Germany, and the US. Key findings: 64% of global respondents feel positive about AI's impact on human health, Gen Z shows divergent views, and trust in health authorities varies by country.
The study identifies three emotional mindsets—Optimists, Rationalists, Skeptics—and stresses transparency and human accountability as critical to building societal acceptance for innovations in AI, cell and gene therapy, new genomic techniques, and cultivated meat.
Bayer Canada (OTC: BAYRY) is funding the Bayer Entrance Award to cover full tuition for one student in the inaugural Simon Fraser University School of Medicine class, which begins with 48 students on the SFU Surrey campus in summer 2026; a permanent facility is planned by 2030.
The award targets applicants demonstrating leadership, service, and financial need to help address primary care shortages in British Columbia.
Bayer (OTC: BAYRY) announced a leadership change in its Pharmaceuticals Worldwide Markets organization, appointing Nelson Ambrogio as President of Bayer U.S. Pharmaceuticals effective May 1, 2026. Ambrogio moves from President of global Radiology and will report to Sebastian Guth.
Ambrogio will lead commercial pharmaceutical operations in the U.S., focusing on prostate cancer, cardiovascular care, women’s healthcare and the company’s future secondary stroke prevention portfolio. He will join the Worldwide Markets Leadership Team as Bayer seeks to accelerate U.S. growth.